Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Letrozole
All products: general benefit
Apo-Letrozole · DIN 02358514 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Letrozole · DIN 02358514
Manufacturer: Apotex Inc.; listing date 2011-05-19
Health Canada: Marketed since 2020-11-24 · brand APO-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Letrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02358514)
Source record
DIN 02358514: Apo-Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id APX
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02358514
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84356
Interchangeable products
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended November 7, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02358514
Shortage record checked October 6, 2026
Femara · DIN 02231384 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Femara · DIN 02231384
Manufacturer: Novartis Pharma Canada Inc.; listing date 1998-12-31
Health Canada: Marketed since 1997-09-02 · brand FEMARA · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02231384)
Source record
DIN 02231384: Femara
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id NOV
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $8.9293; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02231384
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50695
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02231384
Shortage record checked October 6, 2026
Jamp Letrozole Tablets · DIN 02541912 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Letrozole Tablets · DIN 02541912
Manufacturer: Jamp Pharma Corporation; listing date 2024-10-31
Health Canada: Marketed since 2024-08-20 · brand JAMP LETROZOLE TABLETS · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Letrozole Tablets: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02541912)
Source record
DIN 02541912: Jamp Letrozole Tablets
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id JPC
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02541912
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103052
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended April 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02541912
Shortage record checked October 6, 2026
Letrozole · DIN 02504472 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Letrozole · DIN 02504472
Manufacturer: Sanis Health Inc.; listing date 2021-05-31
Health Canada: Marketed since 2026-02-25 · brand LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordLetrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02504472)
Source record
DIN 02504472: Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id SAI
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02504472
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99389
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended May 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02504472
Shortage record checked October 6, 2026
Letrozole · DIN 02524244 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Letrozole · DIN 02524244
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2022-09-29
Health Canada: Marketed since 2022-07-18 · brand LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordLetrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02524244)
Source record
DIN 02524244: Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id SIV
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02524244
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101329
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: active shortage (reported August 15, 2024, last updated November 20, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02524244
Shortage record checked October 6, 2026
Letrozole Tablets USP · DIN 02338459 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Letrozole Tablets USP · DIN 02338459
Manufacturer: Accord Healthcare Inc.; listing date 2010-07-20
Health Canada: Marketed since 2014-05-03 · brand ACH-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Accord healthcare inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordLetrozole Tablets USP: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02338459)
Source record
DIN 02338459: Letrozole Tablets USP
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id ACH
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02338459
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82411
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended December 29, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02338459
Shortage record checked October 6, 2026
Mar-Letrozole · DIN 02373424 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Letrozole · DIN 02373424
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2012-01-19
Health Canada: Marketed since 2022-02-09 · brand MAR-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMar-Letrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02373424)
Source record
DIN 02373424: Mar-Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id MAR
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02373424
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85857
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended May 1, 2019); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02373424
Shortage record checked October 6, 2026
Mint-Letrozole · DIN 02508109 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Letrozole · DIN 02508109
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2021-10-29
Health Canada: Marketed since 2026-05-05 · brand MINT-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Letrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02508109)
Source record
DIN 02508109: Mint-Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id MIN
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02508109
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99746
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended May 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02508109
Shortage record checked October 6, 2026
NRA-Letrozole · DIN 02520486 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Letrozole · DIN 02520486
Manufacturer: Nora Pharma; listing date 2022-06-30
Health Canada: Marketed since 2022-03-25 · brand NRA-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNRA-Letrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02520486)
Source record
DIN 02520486: NRA-Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id NRA
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02520486
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100968
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02520486
Shortage record checked October 6, 2026
Nat-Letrozole · DIN 02421585 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Nat-Letrozole · DIN 02421585
Manufacturer: Natco Pharma (Canada) Inc.; listing date 2015-04-30
Health Canada: Marketed since 2015-02-03 · brand NAT-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Natco pharma (canada) inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNat-Letrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02421585)
Source record
DIN 02421585: Nat-Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id NAT
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02421585
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90623
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02421585
Shortage record checked October 6, 2026
PMS-Letrozole · DIN 02309114 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Letrozole · DIN 02309114
Manufacturer: Pharmascience Inc.; listing date 2010-07-20
Health Canada: Marketed since 2010-04-28 · brand PMS-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Letrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02309114)
Source record
DIN 02309114: PMS-Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id PMS
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02309114
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79471
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended February 23, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02309114
Shortage record checked October 6, 2026
Riva-Letrozole · DIN 02398656 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Riva-Letrozole · DIN 02398656
Manufacturer: Laboratoire Riva Inc.; listing date 2021-08-31
Health Canada: Marketed since 2024-07-03 · brand RIVA-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Laboratoire riva inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRiva-Letrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02398656)
Source record
DIN 02398656: Riva-Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id RIA
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02398656
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88359
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended March 27, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02398656
Shortage record checked October 6, 2026
Sandoz Letrozole · DIN 02344815 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Letrozole · DIN 02344815
Manufacturer: Sandoz Canada Inc.; listing date 2010-06-14
Health Canada: Marketed since 2010-04-27 · brand SANDOZ LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Letrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02344815)
Source record
DIN 02344815: Sandoz Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id SDZ
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02344815
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83029
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended August 10, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02344815
Shortage record checked October 6, 2026
Teva-Letrozole · DIN 02343657 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Letrozole · DIN 02343657
Manufacturer: Teva Canada Limited; listing date 2013-06-27
Health Canada: Marketed since 2013-07-08 · brand TEVA-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Letrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02343657)
Source record
DIN 02343657: Teva-Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id TEV
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02343657
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82909
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: resolved shortage (ended March 10, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02343657
Shortage record checked October 6, 2026
Jamp-Letrozole · DIN 02373009 · 2.5 mg · tablet
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Letrozole · DIN 02373009
Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27
Health Canada: Dormant since 2026-08-03 · brand JAMP-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Letrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02373009)
Source record
DIN 02373009: Jamp-Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id JPC
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02373009
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85813
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02373009
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 3, 2026 — choose a marketed DIN from the same-category list.
Med-Letrozole · DIN 02322315 · 2.5 mg · tablet
General benefitDormant since May 25, 2018 · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Med-Letrozole · DIN 02322315
Manufacturer: Generic Medical Partners Inc.; listing date 2010-07-20
Health Canada: Dormant since 2018-05-25 · brand MED-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Generic medical partners inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMed-Letrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02322315)
Source record
DIN 02322315: Med-Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id GMP
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02322315
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80777
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02322315
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since May 25, 2018 — choose a marketed DIN from the same-category list.
Zinda-Letrozole · DIN 02378213 · 2.5 mg · tablet
General benefitDormant since July 17, 2018 · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Zinda-Letrozole · DIN 02378213
Manufacturer: Stason Pharmaceuticals Inc., Irvine; listing date 2014-01-03
Health Canada: Dormant since 2018-07-17 · brand ZINDA-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Stason pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordZinda-Letrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02378213)
Source record
DIN 02378213: Zinda-Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id STA
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02378213
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86404
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02378213
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 17, 2018 — choose a marketed DIN from the same-category list.
CCP-Letrozole · DIN 02459884 · 2.5 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.Discontinued August 3, 2023 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2023-08-03 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
CCP-Letrozole · DIN 02459884
Manufacturer: CellChem Pharmaceuticals Inc.; listing date 2018-01-31
Health Canada: Cancelled post market since 2023-08-03 · brand CCP-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Cellchem pharmaceuticals inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCCP-Letrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02459884)
Source record
DIN 02459884: CCP-Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id CCP
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02459884
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94719
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02459884
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 3, 2023 — choose a marketed DIN from the same-category list.
Letrozole · DIN 02348969 · 2.5 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-18 — choose a marketed DIN from the same-category list.Discontinued June 18, 2018 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-18 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-06-18 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Letrozole · DIN 02348969
Manufacturer: Cobalt Pharmaceuticals Company; listing date 2010-07-20
Health Canada: Cancelled post market since 2018-06-18 · brand LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Actavis pharma company · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordLetrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02348969)
Source record
DIN 02348969: Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id COB
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02348969
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83427
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Ran-Letrozole · DIN 02372282 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02348969
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 18, 2018 — choose a marketed DIN from the same-category list.
Ran-Letrozole · DIN 02372282 · 2.5 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2022-11-22 — choose a marketed DIN from the same-category list.Discontinued November 22, 2022 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-11-22 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-11-22 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Letrozole · DIN 02372282
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2011-12-15
Health Canada: Cancelled post market since 2022-11-22 · brand TARO-LETROZOLE · ATC L02BG04 LETROZOLE · form Tablet · route Oral · ingredients LETROZOLE 2.5 MG · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRan-Letrozole: Formulary list price $1.38 per unit (the source does not state the unit; exact figure $1.3780). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02372282)
Source record
DIN 02372282: Ran-Letrozole
Raw flags: sec3=Y
Item: 100000116; group id 169; item number 0286; lccId None; manufacturer id RAN
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3780; ministry $1.3780
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02372282
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85742
Interchangeable products
Apo-Letrozole · DIN 02358514 · $1.3780
CCP-Letrozole · DIN 02459884 · $1.3780
Femara · DIN 02231384 · $1.3780
Jamp Letrozole Tablets · DIN 02541912 · $1.3780
Jamp-Letrozole · DIN 02373009 · $1.3780
Letrozole · DIN 02348969 · $1.3780
Letrozole · DIN 02504472 · $1.3780
Letrozole · DIN 02524244 · $1.3780
Letrozole Tablets USP · DIN 02338459 · $1.3780
Mar-Letrozole · DIN 02373424 · $1.3780
Med-Letrozole · DIN 02322315 · $1.3780
Mint-Letrozole · DIN 02508109 · $1.3780
NRA-Letrozole · DIN 02520486 · $1.3780
Nat-Letrozole · DIN 02421585 · $1.3780
PMS-Letrozole · DIN 02309114 · $1.3780
Riva-Letrozole · DIN 02398656 · $1.3780
Sandoz Letrozole · DIN 02344815 · $1.3780
Teva-Letrozole · DIN 02343657 · $1.3780
Zinda-Letrozole · DIN 02378213 · $1.3780
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02372282
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 22, 2022 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (L02B, L02BG): coverage varies; not interchangeable
- Anastrozole (Arimidex): general benefit
- Exemestane (Aromasin): general benefit
- Abiraterone (Zytiga): general benefit
- Bicalutamide (Casodex): general benefit, not a benefit
- Degarelix (Firmagon): general benefit
- Flutamide (Euflex): general benefit, not a benefit
3 more in the class list below
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered
Matched class: 10:00 ANTINEOPLASTIC AGENTS
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE
Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE
10:00 ANTINEOPLASTIC AGENTS
· 18 products · General benefit · strengths: 1mg · Tab
· 3 products · General benefit · strengths: 25mg · Tab
· 18 products · General benefit · strengths: 250mg, 500mg · Tab
· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab
· 2 products · General benefit · strengths: 80mg, 120mg · Pd for Inj-Vial Pk
· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab
· 6 products · General benefit · strengths: 50mg/mL · Inj Sol
· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 10mg, 20mg · Tab
· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg · Cap
· 1 products · General benefit · strengths: 50mg · Cap
· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk
· 1 products · General benefit · strengths: 2mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 10:00
and 34 more
Full class listing
Related classes:
Same formulary class, not same indication: class membership alone does not establish equivalent uses.